Drugs / HPV9
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05496231 | Aug 2022 → Feb 2024 | cervical intraepithelial neoplasia | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPV9 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05496231 ↗ |
| Modality | Vaccine | “HPV9 investigational adjuvanted vaccine” NCT05496231 ↗ |
| Route | Intramuscular | “were administered intramuscularly” NCT05496231 ↗ |